Mesoblast (NASDAQ:MESO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Mesoblast (NASDAQ:MESO – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

Other analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an overweight rating and issued a $23.00 price target on shares of Mesoblast in a research note on Wednesday, February 1st. William Blair assumed coverage on Mesoblast in a research note on Thursday, March 9th. They issued an outperform rating and a $8.00 price target on the stock. Chardan Capital reaffirmed a sell rating and issued a $2.50 price target on shares of Mesoblast in a research note on Wednesday, March 1st. Finally, Jefferies Financial Group lowered Mesoblast from a buy rating to a hold rating in a research note on Tuesday, December 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $10.13.

Mesoblast Price Performance

Mesoblast stock opened at $3.10 on Thursday. Mesoblast has a 12 month low of $2.14 and a 12 month high of $4.94. The business has a 50 day simple moving average of $3.37 and a 200-day simple moving average of $3.18. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.43 and a current ratio of 1.43.

Mesoblast (NASDAQ:MESO – Get Rating) last issued its quarterly earnings results on Monday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $2.13 million during the quarter, compared to analyst estimates of $1.50 million. Mesoblast had a negative return on equity of 16.52% and a negative net margin of 1,068.42%. Analysts anticipate that Mesoblast will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MESO. BlackRock Inc. lifted its stake in shares of Mesoblast by 20.8% in the 1st quarter. BlackRock Inc. now owns 864,638 shares of the company’s stock valued at $3,649,000 after purchasing an additional 149,023 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Mesoblast by 132.6% in the 2nd quarter. Millennium Management LLC now owns 42,690 shares of the company’s stock valued at $95,000 after purchasing an additional 24,336 shares during the last quarter. Ronit Capital LLP acquired a new position in shares of Mesoblast in the 3rd quarter valued at $382,000. Delaney Dennis R acquired a new position in shares of Mesoblast in the 3rd quarter valued at $61,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Mesoblast in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 2.60% of the company’s stock.

About Mesoblast

(Get Rating)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.